## CDK2 inhibition demonstrates RB-independent clinical efficacy in CDK4/6 inhibitor-resistant HR-positive/HER2-negative breast cancer

# Authors
Dejan Juric 1, Kazi N. Islam 1,2,\*, Ioanna Μ. Gkotinakou 1,2,\*, Alice Zheng 1,2, Hanjun Lee 2,3,4, Sneha Saxena 1,2, Johannes Kreuzer 1,2, Robert Morris 1,2, Connor G. McGrath 1,2, Nicholas Chevalier 1, Allison M. Kehlmann 1, Anastasia Stavridi 5, Shahein H. Tajmir 1, Marcello Stanzione 1,2, Eric Zaniewski 1,2, Sidney Mahan 6, Karl Hodel 7, Maci Meyers 7, Srihari Sampath 7, Christian Schmedt 7, Tun Tun Lin 8, Feng Liu 8, Todd VanArsdale 8, Steven J. Isakoff 1, Amy H. Comander 1, Janice S Kim 1, Seth A. Wander 1, Erik S. Knudsen 6, Agnieszka K. Witkiewicz 6, Lee Zou 1,2, Aaron N. Hata1,2,  Michael S. Lawrence 1,2,3, Wilhelm Haas 1,2, Andreas Varkaris 1,\#, Ioannis Sanidas 1,2,\#,†


# Affiliations

1 Mass General Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA

2 Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA

3 Broad Institute of MIT and Harvard, Cambridge, MA

4 Department of Biology, Massachusetts Institute of Technology, Cambridge, MA

5 Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

6 Roswell Park Comprehensive Cancer Center, Buffalo, NY

7 Function Oncology, San Diego, CA

8 Pfizer Inc., La Jolla, CA

\* Contributed equally.

\# Contributed equally.
